证券代码：301267 证券简称：华厦眼科 公告编号：2026-003 1、审议通过《关于选举公司第四届董事会董事长的议案》 华厦眼科医院集团股份有限公司 第四届董事会第一次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 华厦眼科医院集团股份有限公司（以下简称"公司"）于2026年1月14日召 开了2026年第一次临时股东会和2026年第一次职工代表大会，选举产生了第四 届董事会非职工代表董事和职工代表董事，共同组成了公司第四届董事会。经 全体董事一致同意，公司第四届董事会第一次会议于2026年1月14日以现场会议 与通讯会议相结合的方式在公司会议室召开。本次会议应出席董事7名，实际出 席董事7名（其中：委托出席董事1名，董事苏庆灿先生因个人原因无法亲自出 席会议，委托董事陈凤国先生出席会议并代为行使表决权）；公司高管列席了 本次会议。经全体参会董事一致推举，本次会议由陈凤国先生主持，会议的召 集、召开符合《中华人民共和国公司法》（以下简称"《公司法》"）《公司 章程》等有关规定。 二、董事会会议审议情况 全体与会董事以投 ...

Core Viewpoint - The "2026 Maritime Light" academic conference on optometry and visual science highlighted Huaxia Eye Hospital's achievements in refractive surgery, showcasing its innovative practices and clinical quality, which earned multiple prestigious awards [1][4][24]. Group 1: Awards and Recognition - Huaxia Eye Hospital received the "High-Quality Development Contribution Award" for performing over 7,000 new SMILE pro surgeries, reflecting its commitment to standardized, safe, and high-quality surgical practices [4]. - The Xiamen University Affiliated Xiamen Eye Center completed over 3,500 surgeries, while Chengdu Aidi Eye Hospital and Zhengzhou Huaxia Vision Eye Hospital completed over 1,500 and 1,300 surgeries respectively, earning them the "High-Quality Development Contribution Award" for exceeding 1,000 cases [8]. - Huaxia Eye Hospital was recognized with the "Non-Public Medical EVO ICL Project Innovation Breakthrough Award" for its extensive experience and advancements in ICL technology since 2010 [15]. Group 2: Technological Advancements - The hospital introduced the new EVO+ ICL (V5) technology, establishing a nationwide clinical application network and enhancing its leadership in refractive surgery [12]. - The launch of the "Large Optical Zone Intraocular Lens ICL (V5)" technology was a significant milestone, showcasing Huaxia Eye Hospital's expertise and experience in the field [11]. Group 3: Academic Contributions - Huaxia experts actively participated in various academic sessions, demonstrating their influence and technical capabilities in the field of refractive surgery [23]. - The hospital's commitment to academic exchange was evident through its involvement in specialized discussions and practical training sessions during the conference [21][23]. Group 4: Strategic Development - Huaxia Eye Hospital's success is attributed to over 20 years of dedication in the refractive surgery field, focusing on the integration of technology, talent, platform, and service [24]. - The hospital aims to enhance its dual strategy of "corneal laser surgery" and "intraocular lens surgery," accelerating the clinical research of EVO+ ICL (V5) and expanding the application of advanced technologies like new SMILE pro and all-light shaping [24].

Group 1 - WuXi AppTec (药明康德) is a leading global pharmaceutical R&D outsourcing company with a comprehensive layout in AI healthcare, integrating AI technology throughout the drug development process [1] - The AI drug discovery platform developed by WuXi AppTec utilizes machine learning to analyze vast compound data, significantly shortening the early development cycle of small molecules and biologics [1] - The platform has been applied in new drug development projects for oncology and neurodegenerative diseases [1] Group 2 - Aier Eye Hospital (爱尔眼科) is a leading domestic eye care chain focusing on the intelligent upgrade of the entire eye diagnosis and treatment process through AI [2] - The AI fundus screening system developed by Aier can accurately identify common eye diseases with an accuracy rate exceeding 95%, implemented in over a thousand grassroots eye clinics and health check centers nationwide [2] - The company also utilizes AI technology to create personalized correction plans for myopia patients and enhance the precision and safety of surgeries [2] Group 3 - Kanglong Chemical (康龙化成) is a core player in the domestic pharmaceutical R&D outsourcing sector, leveraging AI technology to enhance R&D service efficiency [3] - The AI drug development platform integrates molecular simulation and machine learning, reducing compound screening cycles from months to weeks [3] - AI is also used to construct disease models and simulate drug metabolism processes, improving data accuracy and reducing animal usage [3] Group 4 - Tigermed (泰格医药) is a leading clinical trial CRO in China, focusing on the intelligent transformation of the entire clinical trial process through AI [4] - The AI clinical trial management system enables intelligent project initiation, patient recruitment, and data management, improving recruitment efficiency by over 30% [4] - AI algorithms are employed for real-time monitoring of clinical trial data, providing precise risk warnings and decision-making support for pharmaceutical companies [4] Group 5 - Kelaiying (凯莱英) is a global leader in the pharmaceutical CDMO sector, applying AI technology to enhance drug production and R&D [5] - AI algorithms are used to design optimal chemical synthesis pathways, reducing production costs and enhancing safety and yield [5] - The company has developed an AI drug R&D platform to predict the physicochemical properties and biological activity of compounds, aiding in the rapid selection of candidate drug molecules [5] Group 6 - Meinian Health (美年健康) is a leading health checkup company in China, with AI healthcare as a core driver for upgrading its services [6] - The AI intelligent health check system covers the entire process from appointment scheduling to health report interpretation, with AI imaging diagnosis achieving accuracy close to that of professional doctors [6] - The company integrates national health check big data to conduct chronic disease trend research, supporting public health decision-making [6] Group 7 - Zhaoyan New Drug (昭衍新药) is a leader in non-clinical safety evaluation of drugs, focusing on the intelligent upgrade of drug safety evaluation through AI [7] - The AI drug safety prediction platform integrates vast toxicology data and machine learning algorithms to predict potential toxicity of new drugs early [7] - AI technology is also used for intelligent monitoring of experimental animals, enhancing data accuracy and reliability [7] Group 8 - BGI Genomics (华大基因) is a leading global player in the field of gene sequencing, deeply integrating AI technology with gene sequencing [8] - AI algorithms are applied to analyze gene sequencing data, significantly improving the efficiency and accuracy of genetic disease diagnosis [8] - The company has developed a big data platform to support precision medicine and drug development through AI analysis of vast genetic data [8] Group 9 - Tongce Medical (通策医疗) is a leading domestic dental care chain focusing on the intelligent upgrade of dental diagnosis and treatment through AI [9] - The AI dental imaging diagnosis system can automatically analyze dental CT and panoramic images, assisting dentists in making accurate diagnoses [9] - The company also utilizes AI technology to optimize patient appointment and triage systems, enhancing patient flow and reducing wait times [9] Group 10 - Haoyuan Pharmaceutical (皓元医药) is a core player in the domestic pharmaceutical reagents and raw materials sector, focusing on intelligent upgrades in drug and reagent development through AI [10] - The AI molecular design platform significantly shortens the discovery cycle of lead compounds in drug development [10] - AI technology is also used to optimize inventory management, reducing costs and improving supply chain efficiency [10] Group 11 - Jiuzhou Pharmaceutical (九洲药业) is an important player in the domestic CDMO sector, focusing on the intelligent upgrade of drug production and R&D through AI [11] - AI algorithms are utilized to design optimal chemical synthesis pathways, enhancing yield and reducing production costs [11] - The company has developed an AI drug R&D platform to predict the biological activity and pharmacokinetic properties of compounds [11] Group 12 - KingMed Diagnostics (金域医学) is a leading third-party medical testing company in China, with AI healthcare applications throughout the testing process [12] - The AI data analysis system can automatically analyze vast testing data, quickly identifying abnormal indicators and generating reports [12] - The company also integrates national testing big data to conduct epidemiological research, supporting public health prevention efforts [12] Group 13 - Dian Diagnostics (迪安诊断) is a leading third-party medical diagnostic service provider, with AI healthcare as a core driver for enhancing diagnostic capabilities [13] - The AI diagnostic platform covers multiple fields, achieving over 90% accuracy in identifying tumor cells and infectious lesions [13] - AI technology is also used to optimize testing processes, improving laboratory throughput and efficiency [13] Group 14 - Chengdu XianDao (成都先导) is a leading new drug development company, deeply integrating AI technology with its core DNA-encoded compound library business [14] - AI algorithms are used to design DNA-encoded compound libraries, significantly improving screening efficiency and hit rates [14] - The company has developed a cloud computing platform for AI drug R&D, providing intelligent services to global pharmaceutical companies [14] Group 15 - Sanbo Brain Science (三博脑科) is a specialized medical service institution in the field of neurosurgery, with AI applications in both healthcare and brain-computer interface technology [15] - The AI neuroimaging diagnosis system can automatically analyze brain CT and MRI images, assisting in diagnosing neurological diseases [15] - The company collaborates with research institutions to conduct clinical studies on brain-computer interfaces, helping patients regain motor function [15] Group 16 - Innovation Medical (创新医疗) is a comprehensive medical service enterprise focusing on intelligent upgrades in rehabilitation and orthopedic diagnosis through AI [16] - The AI rehabilitation assessment system collects patient movement data to automatically evaluate rehabilitation effectiveness and adjust training plans [16] - AI technology is also used to analyze X-ray and CT images for orthopedic diagnosis, enhancing the precision of surgical planning [16]

Core Viewpoint - The establishment of the Traditional Chinese Medicine (TCM) Eye Clinic at Qingdao Huaxia Eye Hospital marks a significant step towards the deep integration of traditional and modern medicine, providing a more diverse, systematic, and personalized health pathway for eye disease patients [1][3]. Group 1: Hospital's Strategic Initiatives - The hospital is responding to the national call for the collaborative development of TCM and Western medicine by establishing the TCM Eye Clinic, which enhances its service offerings and meets the public's demand for integrated healthcare [3]. - The establishment of the TCM Eye Clinic is seen as a new starting point for high-quality service, with plans for clinical, research, and talent development to create a comprehensive eye health service model that integrates prevention, treatment, and rehabilitation [5]. Group 2: Leadership and Expertise - Dr. Li Qing has been appointed as the head of the TCM Eye Clinic, bringing extensive clinical experience and recognition in TCM ophthalmology, which strengthens the professional foundation and confidence in this emerging discipline [7]. Group 3: Service Offerings - The TCM Eye Clinic will focus on three main areas: 1. Providing TCM therapies for common issues such as dry eye, visual fatigue, and myopia prevention [9]. 2. Offering collaborative interventions for chronic eye diseases like age-related macular degeneration and diabetic retinopathy, combining TCM with standard Western treatments to improve symptoms and quality of life [9]. 3. Promoting eye disease prevention and health management through TCM principles, including health education and body constitution identification [9]. Group 4: Future Outlook - The hospital aims to leverage the establishment of the TCM Eye Clinic to explore innovative paths for integrating TCM and Western medicine in eye health, continuously enhancing diagnostic and service quality for the local community [11].

Core Viewpoint - In 2025, the Chinese stock market showed remarkable performance, with the Shanghai Composite Index increasing by 18.4% year-on-year, reaching 3968.84 points by December 31, 2025 [1] Group 1: Performance of Xiamen Listed Companies - In 2025, 70 listed companies in Xiamen performed well, with 42 companies outperforming the market [1] - 15 listed companies in Xiamen reached historical highs in stock prices, reflecting strong operational fundamentals and growth potential [2] - The total market capitalization of the 70 listed companies in Xiamen was 9030.35 billion, a 44.1% increase compared to the previous year [2] - 30 companies had a market capitalization exceeding 100 billion, accounting for over 40% of the total, with Xiamen Tungsten leading at 651.86 billion [2] - 56 companies saw an increase in market capitalization, with 13 companies experiencing growth exceeding 100% [2] Group 2: New Listings and Recognition - In 2025, Xiamen added 6 new listed companies, the highest in nearly four years, including 2 A-share companies [5] - Among the 70 listed companies, 26 were recognized as national "specialized and innovative" small giant enterprises, and over 80% were high-tech enterprises [6] - Several Xiamen listed companies received honors, including Xiamen Tungsten and Jibite, recognized for best practices in corporate governance [7][9] - The number of listed companies in Xiamen has surpassed 100, with 70 being domestic listed companies, representing about 40% of the provincial total [10]

2026年1月5日，博士伦公司事业部总监Garry Lau、国药瑞德医疗器材有限公司总经理朱鼎宏一行到访 华厦眼科。集团领导陈凤国携相关部门负责人热情接待，围绕眼病手术领域的技术革新、临床应用与服 务质量提升，展开深度座谈交流。此次战略对话旨在进一步深化战略合作，共同探索眼病手术诊疗新模 式，推动眼病服务向更高品质、更精准、更可及的方向迈进。 共叙合作情谊，共话发展愿景 集团领导陈凤国对博士伦与国药瑞德一行的到访表示热烈欢迎。他指出，"一切以病人为中心"是华厦眼 科始终不变的服务宗旨。"十四五"期间，我国CSR(每百万人白内障手术例数)不断提高，但较发达国家 仍有较大差距。从长远看，提升眼病手术的普及率与技术水平仍是行业重要使命。 他强调，提升眼病手术诊疗服务质量是双方共同的责任与追求，期待通过更全面的资源整合，探索高品 质眼病服务新路径，造福更多眼疾患者。 博士伦事业部总监Garry Lau深情回顾，博士伦与华厦眼科是22载的"老朋友"，彼此的信任早已根深叶 茂。他表示，华厦眼科拥有顶尖的专家团队、强大的临床实力与广泛的基层医疗网络覆盖能力，是国内 眼科医疗领域的佼佼者，也是博士伦创新产品的优先合作伙伴。 ...

Group 1: Pharmaceutical and Biotech Industry - The pharmaceutical and biotech industry in China is entering a new era of innovative drugs, transitioning from a generics-dominated market (pre-2018) to a focus on innovation from 2026 onwards, with significant growth expected in innovative drug development and commercialization [5] - The report highlights the importance of monitoring the launch rhythm of innovative drugs, competitive landscape, and key clinical data in 2026, as well as the impact of international business development (BD) transactions on cash flow [5] - The CXO and upstream scientific reagent sectors are expected to benefit from the rapid development of innovative drugs, maintaining a strong growth momentum [5] Group 2: Medical Device Industry - The medical device industry has faced significant challenges over the past three years, including anti-corruption measures and price reductions, leading to a decline in profitability for listed companies [6] - However, since 2025, there has been a gradual recovery in the industry, with improved profitability expected in 2026 as negative factors clear and new technologies like brain-computer interfaces and AI products emerge [6] - The overseas market is anticipated to become a new growth point due to companies' investments in capacity, channels, and branding [6] Group 3: Medical Services Consumption - The medical services consumption sector has been under pressure from macroeconomic conditions and policy changes, but is expected to recover as domestic consumption gradually improves [7] - The report emphasizes the potential for specialized hospitals with brand and chain advantages to lead growth in 2026, alongside the retail service market benefiting from the diversification of services [7] - A list of recommended stocks includes companies like Kelun Pharmaceutical, Rongchang Bio, and Yifeng Pharmacy, which are positioned to capitalize on these trends [7] Group 4: Manufacturing PMI Insights - The manufacturing PMI for December 2025 was reported at 50.1%, indicating a recovery from the previous value of 49.2%, driven by improved demand and supply conditions [10][11] - Factors contributing to this increase include positive expectations from recent important meetings, a recovery in trade relations, and increased pre-holiday inventory demands [10][12] - High-tech manufacturing sectors showed significant growth, with the high-tech PMI reaching 52.5%, indicating strong performance in this segment [13] Group 5: Economic Policy and Market Outlook - The central economic work conference has set a positive tone for 2026, emphasizing the importance of domestic demand and investment stabilization [15] - The report suggests that upcoming policies will focus on enhancing consumer spending and investment, with potential adjustments in housing policies expected to support the market [15] - The market is advised to focus on sectors benefiting from technological advancements and domestic consumption trends, particularly in light of anticipated policy support [16]

Group 1 - The core viewpoint of the news is that Huaxia Eye Hospital has shown a slight decline in stock price and has experienced significant financing activities, indicating a mixed sentiment among investors [1] - As of December 31, Huaxia Eye Hospital's stock price fell by 0.06%, with a trading volume of 55.95 million yuan. The net financing buy was -4.74 million yuan, indicating more financing repayment than buying [1] - The total financing and securities balance for Huaxia Eye Hospital reached 192 million yuan, with the financing balance accounting for 1.26% of the circulating market value, which is above the 90th percentile of the past year [1] Group 2 - As of September 30, the number of shareholders for Huaxia Eye Hospital increased to 21,200, a rise of 0.58%, while the average circulating shares per person decreased by 0.57% to 15,489 shares [2] - For the period from January to September 2025, Huaxia Eye Hospital reported a revenue of 3.272 billion yuan, reflecting a year-on-year growth of 2.83%, and a net profit attributable to shareholders of 434 million yuan, up by 3.04% [2] - Since its A-share listing, Huaxia Eye Hospital has distributed a total of 507 million yuan in dividends [3]

Group 1 - The core point of the news is that Huaxia Eye Hospital's stock has experienced a decline of 1.04%, with a total market value of 15.128 billion yuan and a cumulative drop of 0.6% over the last three days [1] - Huaxia Eye Hospital Group, established on August 12, 2004, specializes in ophthalmology services, with revenue composition as follows: refractive projects 36.90%, comprehensive optometry projects 24.04%, cataract projects 20.14%, posterior segment projects 12.94%, and others 5.99% [1] - The stock's trading volume was 36.5619 million yuan, with a turnover rate of 0.31% [1] Group 2 - Huaxia Eye Hospital's major circulating shareholder is Huabao Fund, which reduced its holdings in the Huabao CSI Medical ETF (512170) by 1.1664 million shares, now holding 7.1388 million shares, representing 2.17% of circulating shares [2] - The estimated floating loss for Huabao CSI Medical ETF today is approximately 1.3564 million yuan, with a cumulative floating loss of 785,300 yuan during the three-day decline [2] - The Huabao CSI Medical ETF was established on May 20, 2019, with a current scale of 26.404 billion yuan and a year-to-date return of 5.42%, ranking 3760 out of 4195 in its category [2]

Core Viewpoint - Huaxia Eye Hospital announced the approval of several key resolutions during the 12th meeting of its third board of directors, including the election of the fourth board of directors and the termination of the 2025 employee stock ownership plan [1] Group 1 - The company approved the proposal for the election of non-independent director candidates for the fourth board of directors [1] - The company approved the proposal for the election of independent director candidates for the fourth board of directors [1] - The company decided to terminate the implementation of the 2025 employee stock ownership plan [1]